The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
This sBLA submission is supported by clinical, pre-clinical, and manufacturing data demonstrating the safety, tolerability, and immunogenicity of the bivalent vaccine.
N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.
More than 5 lakh patients availed the benefit of queue-less OPD registration using this service
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
Ayurveda is one of the most advanced sciences of its times
Subscribe To Our Newsletter & Stay Updated
